Personalized mutation tracking could spot relapse sooner in bone marrow cancer patients

NCT ID NCT02872662

Completed Knowledge-focused Sponsor: Nordic MDS Group Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 308 people with myelodysplastic syndromes (MDS) who had a stem cell transplant. Researchers identified each patient's unique genetic mutations and then monitored those mutations in blood and bone marrow samples after transplant. The goal was to see if rising mutation levels could signal a relapse before it becomes obvious, potentially allowing earlier treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a way to catch relapse earlier in MDS patients after transplant, potentially improving outcomes.
What could go wrong: This is an observational study, not a treatment trial. It may not change patient outcomes directly, and the methods may not be widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bilateral multicystic dysplastic kidney myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm spondylocarpotarsal synostosis syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MDS MRD SCT

Contacts and locations

Locations

Department of Hematology and Coagulation, Sahlgrenska University hospital

Gothenburg, 413 45, Sweden
Department of Hematology, Aarhus University Hospital

Aarhus, 8000, Denmark
Department of Hematology, Akademiska University Hospital

Uppsala, 751 85, Sweden
Department of Hematology, Karolinska University Hospital

Stockholm, Sweden
Department of Hematology, Lund University Hospital

Lund, 221 85, Sweden
Department of Hematology, Rigshospitalet Univsersity Hospital

Copenhagen, Denmark
Department of Hematology, Rikshospitalet University Hospital

Oslo, 0027, Norway
Department of Medcine, Haukeland University Hospital

Bergen, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.